Bristol-Myers Squibb reached an agreement that could result in the company paying more than $1 billion for exclusive rights to develop a rheumatoid arthritis treatment by privately held Alder.
WSJ.com: US Business, Wall Street Journal: Business
Tue, 11/10/2009 - 6:07am
Bristol-Myers Squibb reached an agreement that could result in the company paying more than $1 billion for exclusive rights to develop a rheumatoid arthritis treatment by privately held Alder.